Abstract:The authors noticed that in Fig. 6, there are similarities between the two images: WT DBS group and APP/PS1 control group in Hoechst staining. This error was inadvertently made during image assembly. The error has now been corrected as shown below. This correction does not affect the results or conclusions of the work. We apologize for any inconvenience caused. The neuroprotective effect of deep brain stimulation at nucleus basalis of Meynert in transgenic mice with Alzheimer's diseaseBrain Stimulation: Basic, Translational, and Clinical Research in NeuromodulationVol. 12Issue 1PreviewAlzheimer's disease (AD) is the most common type of dementia and mainly treated by drugs, while the therapeutic outcomes are very limited. This study aimed to determine the optimized parameters of deep brain stimulation (DBS) which was applied to the treatment of AD and propose the involved mechanisms. Full-Text PDF

Correction: Dominguez-Meijide et al. Pharmacological Modulators of Tau Aggregation and Spreading. Brain Sci. 2020, 10, 858

Correction to: Inhibition of Dectin-1 Ameliorates Neuroinflammation by Regulating Microglia/Macrophage Phenotype After Intracerebral Hemorrhage in Mice

Correction: Cotovio et al. Regulatory Clearance and Approval of Therapeutic Protocols of Transcranial Magnetic Stimulation for Psychiatric Disorders. Brain Sci. 2023, 13, 1029

Erratum: Tejeda-Bayron et al. Activation of Glutamate Transporter-1 (GLT-1) Confers Sex-Dependent Neuroprotection in Brain Ischemia. Brain Sci. 2021, 11, 76

Author Correction: Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Erratum: Effect of the ROCK inhibitor fasudil on the brain proteomic profile in the tau transgenic mouse model of Alzheimer's disease

Correction: Amin et al. Hippocampal and Cerebellar Changes in Acute Restraint Stress and the Impact of Pretreatment with Ceftriaxone. Brain Sci. 2020, 10, 193

Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]

Author Correction: Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy

Author correction to ‘A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease’ [Acta Pharmaceutica Sinica B 12 (2021) 4032‒4044]

Correction: Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurodegenerative disease treatment

Corrigendum to “the Neuroprotective Effect of Deep Brain Stimulation at Nucleus Basalis of Meynert in Transgenic Mice with Alzheimer’s Disease” [brain Stimul 12 (2019) 161–174]

Correction: Thangameeran et al. Examining Transcriptomic Alterations in Rat Models of Intracerebral Hemorrhage and Severe Intracerebral Hemorrhage. Biomolecules 2024, 14, 678

Corrigendum to “central Angiotensin II‐induced Alzheimer‐like Tau Phosphorylation in Normal Rat Brains” [FEBS Lett. 586 (2012) 3737–3745]

Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy: Erratum

Correction: Quintero et al. Changing the Tendency to Integrate the Senses. Brain Sci. 2022, 12, 1384

Correction: Tiwari et al. Neuroprotective Effect of α-Mangostin in Ameliorating Propionic Acid-Induced Experimental Model of Autism in Wistar Rats. Brain Sci. 2021, 11, 288

Correction: He et al. Intranasal Administration of Agomir-let-7i Improves Cognitive Function in Mice with Traumatic Brain Injury. Cells 2022, 11, 1348

Correction: Corrigendum: Opportunities and challenges in modeling human brain disorders in transgenic primates

Correction: Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer’s disease rat induced by amyloid beta 25-35

Correction: Shibly et al. Analysis of Cerebral Small Vessel Changes in AD Model Mice. Biomedicines 2023, 11, 50